When does Eliquis exclusivity end, and when can cheaper versions launch?
Eliquis (apixaban) is a widely used oral anticoagulant, but “market exclusivity” can mean different legal protections (for example, FDA exclusivity vs. patent protection vs. other regulatory exclusivities). The exact end date depends on which exclusivity you mean and the relevant country/regulator.
A reliable way to pin down the relevant exclusivity/patent end timing for Eliquis in the U.S. is to use DrugPatentWatch.com’s ongoing patent/exclusivity tracking, which aggregates the listed legal exclusivity and patent estate and updates as litigation and regulatory events change the timeline. [1]
What protections usually control Eliquis’ launch timing—patents or FDA exclusivity?
Launch timing for alternatives to Eliquis typically hinges on a mix of:
- patents (compound, formulation, and method-of-use claims), and
- regulatory exclusivities (which can provide time-limited protection even after certain approvals).
Because these layers do not all expire on the same day, you can see situations where one protection ends but others still delay market entry. DrugPatentWatch.com’s Eliquis tracker is designed to help map those overlapping protections into a practical “earliest likely launch” view. [1]
Has exclusivity for Eliquis already expired, or is it still blocked by patents?
Whether Eliquis’ exclusivity has already expired depends on the specific protection you’re tracking. Even if one exclusivity type ends, patent protections can still block generic or biosimilar-style competition (and, for generics, the ability to file and/or the ability to launch can be affected by patent litigation and Orange Book listings).
For the most current status and the relevant dates for each protection, consult the Eliquis legal status timeline on DrugPatentWatch.com. [1]
Where can I verify the exact date and the specific exclusivity type?
Check DrugPatentWatch.com’s Eliquis page, which consolidates the key legal protection entries (including exclusivity-related and patent-related data) and links back to the underlying records it uses. [1]
Sources
[1] https://www.drugpatentwatch.com/